Bicara Therapeutics Statistics
Total Valuation
BCAX has a market cap or net worth of $1.44 billion. The enterprise value is $1.02 billion.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, before market open.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCAX has 65.47 million shares outstanding. The number of shares has increased by 225.35% in one year.
| Current Share Class | 65.47M |
| Shares Outstanding | 65.47M |
| Shares Change (YoY) | +225.35% |
| Shares Change (QoQ) | +1.06% |
| Owned by Insiders (%) | 1.95% |
| Owned by Institutions (%) | 68.59% |
| Float | 42.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.05 |
| P/TBV Ratio | 3.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.58, with a Debt / Equity ratio of 0.00.
| Current Ratio | 14.58 |
| Quick Ratio | 14.33 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.88% and return on invested capital (ROIC) is -21.71%.
| Return on Equity (ROE) | -30.88% |
| Return on Assets (ROA) | -20.67% |
| Return on Invested Capital (ROIC) | -21.71% |
| Return on Capital Employed (ROCE) | -38.70% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.34M |
| Employee Count | 103 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BCAX has paid $217,000 in taxes.
| Income Tax | 217,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +50.76% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +50.76% |
| 50-Day Moving Average | 19.68 |
| 200-Day Moving Average | 16.05 |
| Relative Strength Index (RSI) | 52.76 |
| Average Volume (20 Days) | 560,148 |
Short Selling Information
The latest short interest is 9.33 million, so 14.25% of the outstanding shares have been sold short.
| Short Interest | 9.33M |
| Short Previous Month | 9.64M |
| Short % of Shares Out | 14.25% |
| Short % of Float | 22.05% |
| Short Ratio (days to cover) | 15.13 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -155.60M |
| Pretax Income | -137.73M |
| Net Income | -137.95M |
| EBITDA | -155.50M |
| EBIT | -155.60M |
| Earnings Per Share (EPS) | -$2.52 |
Full Income StatementBalance Sheet
The company has $414.80 million in cash and $1.71 million in debt, giving a net cash position of $413.09 million or $6.31 per share.
| Cash & Cash Equivalents | 414.80M |
| Total Debt | 1.71M |
| Net Cash | 413.09M |
| Net Cash Per Share | $6.31 |
| Equity (Book Value) | 401.45M |
| Book Value Per Share | 7.37 |
| Working Capital | 393.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$106.83 million and capital expenditures -$280,000, giving a free cash flow of -$107.11 million.
| Operating Cash Flow | -106.83M |
| Capital Expenditures | -280,000 |
| Depreciation & Amortization | 105,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -107.11M |
| FCF Per Share | -$1.64 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |